Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity

Cancer Cell(2023)10.1016/j.ccell.2023.04.018Source: DataRank Database

Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity is a research paper published in Cancer Cell (2023). On theSindex it has a DataRank of 0. It has been cited 95 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access95 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: bronzeIDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Graham D. Hogg ORCID,Chong Zuo ORCID,Nicholas Borcherding ORCID,John Baer ORCID,Varintra E. Lander ORCID

Live enrichment

PubMed:19910364

National Cancer Institute

Grant: P30CA09184215

National Cancer Institute

Grant: P50CA196510

National Cancer Institute

Grant: R01CA203890

National Cancer Institute

Grant: R01CA273190 R01CA177670

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttp://www.cell.com/article/S1535610823001629/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535610823001629?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610823001629?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10281762/pdf/nihms-1903411.pdf

Related Papers (10)

ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation

Journal of Clinical Investigation(2020)

co-cited

10.1172/jci139333

Viral vector platforms within the gene therapy landscape

Signal Transduction and Targeted Therapy(2021)

co-cited

10.1038/s41392-021-00487-6

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

N/A

0.889DataRank · unranked

Clinical Cancer Research(2021)

co-cited

10.1158/1078-0432.ccr-21-1963

The Evolution of STING Signaling and Its Involvement in Cancer

Trends in Biochemical Sciences(2021)

co-cited

10.1016/j.tibs.2020.12.010

Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma

Clinical Cancer Research(2021)

co-cited

10.1158/1078-0432.ccr-21-1914

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

N/A

0.832DataRank · unranked

Nature Communications(2022)

co-cited

10.1038/s41467-022-30568-1

STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models

N/A

0.774DataRank · unranked

Proceedings of the National Academy of Sciences(2022)

co-cited

10.1073/pnas.2111003119

Non-cell-autonomous cancer progression from chromosomal instability

N/A

0.852DataRank · unranked

Nature(2023)

co-cited

10.1038/s41586-023-06464-z

Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders

Molecular Neurodegeneration(2023)

co-cited

10.1186/s13024-023-00672-x

Epigenetic state determines the in vivo efficacy of STING agonist therapy

Nature Communications(2023)

co-cited

10.1038/s41467-023-37217-1